Work

Osimertinib plus Selumetinib in EGFR -Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)

Year: 2022

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-21-4329

Authors: James Chih-Hsin Yang, Yuichiro Ohe, Chao-Hua Chiu, Xiaoling Ou, Mireille Cantarini, Pasi A. Jänne, Ryan J. Hartmaier, Myung Ju Ahn

Institutions: National Taiwan University, National Taiwan University Hospital, National Cancer Centre Japan, Taipei Veterans General Hospital, AstraZeneca (United Kingdom), Dana-Farber Cancer Institute, AstraZeneca (United States), Samsung Medical Center, Sungkyunkwan University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282929591

FWCI: 1.559

Cites: 35

Cited by: 16

Related to: 10